1 Programs refers to the Company’s current and future therapeutic candidates and technologies, including those that are being developed internally by PureTech and those being advanced within PureTech’s Founded Entities. Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Gallop Oncology, Inc. Vor ownership was calculated on a beneficial ownership basis in accordance with SEC rules as of March 13, 2025.
3 PureTech level cash, cash equivalents and short-term investments excludes cash and cash equivalents at non-wholly owned subsidiary of $0.4m. PureTech level cash, cash equivalents and short-term investments is a non-IFRS measure.